1-4 of 4
Edward D. Agura
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting

Marcello Rotta, Barry E. Storer, Firoozeh Sahebi, Judith A. Shizuru, Benedetto Bruno, Thoralf Lange, Edward D. Agura, Peter A. McSweeney, Michael A. Pulsipher, Parameswaran Hari, Richard T. Maziarz, Thomas R. Chauncey, Frederick R. Appelbaum, Mohamed L. Sorror, William Bensinger, Brenda M. Sandmaier, Rainer F. Storb, David G. Maloney
Journal: Blood
Blood (2009) 113 (14): 3383–3391.
https://doi.org/10.1182/blood-2008-07-170746
Published: 2009
Includes: Supplemental data
Journal Articles

Preliminary Results of Phase II Trial of Clofarabine with Parenteral Busulfan Followed by Allogeneic Related or Unrelated Donor Transplantation for the Treatment of Hematologic Malignancies and Diseases.

Edward D. Agura, MD, R. Brian Berryman, MD, Joseph W. Fay, MD, FACP, Luis A. Pineiro, MD, Estil A. Vance, MD, Mirjana Tadic-Ovcina
Journal: Blood
Blood (2007) 110 (11): 4954.
https://doi.org/10.1182/blood.V110.11.4954.4954
Published: 2007
Journal Articles

Long-Term Outcome of Autologous Followed by Nonmyeloablative Allografting from HLA-Identical Sibling for Multiple Myeloma (MM).

Marcello Rotta, MD, Barry Storer, PhD, Firoozeh Sahebi, MD, Judith A. Shizuru, MD PhD, Bruno Benedetto, MD PhD, Thoralf Lange, MD, Peter A. McSweeney, MD, Michael A. Pulsipher, MD, Parameswaran Hari, MD, Richard T. Maziarz, MD, Edward D. Agura, MD, Thomas Chauncey, MD, Frederick R. Appelbaum, MD, Mohamed L. Sorror, MD, William Bensinger, MD, Brenda M. Sandmaier, MD PhD, Rainer F. Storb, MD, David G. Maloney, MD PhD
Journal: Blood
Blood (2007) 110 (11): 3029.
https://doi.org/10.1182/blood.V110.11.3029.3029
Published: 2007
Journal Articles

Nonmyeloablative Unrelated Donor (URD) Hematopoietic Cell Transplantation (HCT) for the Treatment of Patients (pts) with Poor-Risk, Relapsed or Refractory Multiple Myeloma.

George E. Georges, MD, Michael B. Maris, MD, David G. Maloney, MD, Brenda M. Sandmaier, MD, Mohamed L. Sorror, MD, Judith A. Shizuru, MD, Dietger W. Niederwieser, MD, Edward D. Agura, MD, Benedetto Bruno, MD, Peter A. McSweeney, MD, Michael A. Pulsipher, MD, Thomas R. Chauncey, MD, Barry E. Storer, PhD, Rainer F. Storb, MD
Journal: Blood
Blood (2005) 106 (11): 2893.
https://doi.org/10.1182/blood.V106.11.2893.2893
Published: 2005